Med. praxi. 2016;13(1):8-13 [Interní Med. 2015; 17(2): 64-68]

Combination therapy within metabolic syndrome

prof.MUDr.Miroslav Souček, CSc., MUDr.Ivan Řiháček, Ph.D.
II. interní klinika LF MU a ICRC Fakultní nemocnice u sv. Anny v Brně

Metabolic syndrome is present in the Czech Republic at 32% of males and 24% females. The main consequence of the components of metabolic syndrome and atherosclerosis is the cause of death. An important component of hypertension, for which treatment achieves the target values only in 29,5% of hypertensive patients. To improve this situation may lead combination therapy, especially fixed combinations that can improve compliance to treatment.

Keywords: metabolic syndrome, hypertension, combination therapy, fixed combination

Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, Řiháček I. Combination therapy within metabolic syndrome. Med. praxi. 2016;13(1):8-13.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Filipovský J, Widimský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Hypertenze a kardiovaskulární prevence 2013; 3: 1-15.
    2. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    3. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trialls. Am Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    4. Widimský J, et al. Hypertenze. Praha, Triton 2008; 705 s.
    5. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008; 24: 3543-1557. Go to original source... Go to PubMed...
    6. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011; 53: 220-229. Go to original source...
    7. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2154. Go to original source... Go to PubMed...
    8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34 (28): 2159-2219. Go to original source... Go to PubMed...
    9. Patel A and ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
    10. Hannson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized Trial. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
    11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
    12. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008; 358: 2630-2633. Go to original source... Go to PubMed...
    13. Staessen JA, Fagard R, Thijs L, et al. For the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757-764. Go to original source... Go to PubMed...
    14. Beckett NS, Peters R, Fletcher AE, et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
    15. Farsang C, Picasso Investigators. Blood pressure and metabolit efficacy of fixed-dose combination of perindopril and indapamie in everyday practice. Blood Press. 2013; 22 Suppl 1: 3-10. Go to original source... Go to PubMed...
    16. Dahlöf B, Devereux RB, Kjeldsen SE for the LIFE invetigators: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    17. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    18. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    19. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905. Go to original source... Go to PubMed...
    20. Rothwell PM, Howard SC, Dolan E, et al. Effect of ? blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurology 2010; 9: 469-80. Go to original source... Go to PubMed...
    21. Slíva J. Nová fixní kombinace amlodipinu a atorvastatinu. Hypertenze a kardiovaskulární prevence 2012; 2: 20-23.
    22. Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006; 8 (8): 571-581. Go to original source... Go to PubMed...
    23. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011; 27 (4): 821-833. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.